Globus Medical (NYSE:GMED) Shares Acquired by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Globus Medical, Inc. (NYSE:GMED). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Globus Medical stock on September 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Globus Medical Price Performance

GMED stock traded down $0.77 during midday trading on Wednesday, reaching $75.55. 293,323 shares of the company’s stock traded hands, compared to its average volume of 1,476,438. Globus Medical, Inc. has a fifty-two week low of $57.67 and a fifty-two week high of $101.40. The business has a 50-day moving average price of $78.91 and a two-hundred day moving average price of $81.59. The company has a market capitalization of $10.14 billion, a P/E ratio of 19.32, a PEG ratio of 1.23 and a beta of 0.96.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The firm had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts forecast that Globus Medical, Inc. will post 4.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. BTIG Research restated a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Royal Bank Of Canada reduced their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, October 1st. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Friday. Wells Fargo & Company reduced their price target on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, UBS Group assumed coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Globus Medical presently has an average rating of “Moderate Buy” and a consensus target price of $99.46.

Insider Transactions at Globus Medical

In related news, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James R. Tobin sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the transaction, the director directly owned 15,000 shares in the company, valued at $1,118,700. This trade represents a 66.67% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 18.38% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Elevation Wealth Partners LLC boosted its stake in Globus Medical by 2,178.6% during the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 305 shares during the last quarter. Continuum Advisory LLC bought a new stake in shares of Globus Medical during the 2nd quarter valued at about $25,000. Summit Securities Group LLC purchased a new stake in shares of Globus Medical in the 1st quarter valued at $48,000. Root Financial Partners LLC boosted its holdings in Globus Medical by 291.5% in the first quarter. Root Financial Partners LLC now owns 779 shares of the medical device company’s stock valued at $67,000 after acquiring an additional 580 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Globus Medical by 111.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,199 shares of the medical device company’s stock worth $103,000 after purchasing an additional 632 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Globus Medical

Globus Medical, Inc is a medical device company that develops musculoskeletal solutions for surgeons, hospitals and ambulatory surgery centers. Its primary focus is the design, development and commercialization of products used in spinal surgery, including implants, instruments, navigation systems and robotic-assisted technologies.

The company’s portfolio includes the ExcelsiusGPS robotic navigation platform, Excelsius3D imaging technology, spinal implants and systems for procedures such as deformity correction, degenerative spine treatment and minimally invasive surgery.